Psoriasis: similar safety profile for secukinumab 300 vs 150 mg

  • Zhang L & al.
  • Medicine (Baltimore)
  • 1 Jan 2019

  • curated by Brian Richardson, PhD
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • A systematic review and meta-analysis suggest that secukinumab (Cosentyx) 150 mg and 300 mg are associated with similar risk for adverse events (AEs) in patients with moderate to severe plaque psoriasis.

Why this matters

  • This meta-analysis supports the safety of secukinumab at both doses.

Key results

  • Secukinumab 150 mg and 300 mg were associated with similar risk for any AE (risk ratio [RR], 1.00; P=.94), serious AEs (RR, 1.04; P=.82), and AEs leading to drug discontinuation (RR, 0.98; P=.92).
  • Secukinumab 150 mg and 300 mg were associated with similar risk for infection/infestation (RR, 1.11; P=.09), nasopharyngitis (RR, 1.05; P=.55), headache (RR, 0.92; P=.60), diarrhea (RR, 1.14; P=.55), pruritus (RR, 0.82; P=.33), arthralgia (RR, 0.96; P=.83), upper respiratory tract infection (RR, 0.98; P=.89), hypertension (RR, 1.22; P=.31), nausea (RR, 1.39; P=.42), and cough (RR, 1.46; P=.34).

Study design

  • 7 studies with 2361 participants were included.
  • Funding: None.

Limitations

  • Some heterogeneity between studies.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit